Market closed
Gyre Therapeutics/$GYRE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Gyre Therapeutics
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
Ticker
$GYRE
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
579
ISIN
US4037831033
Website
GYRE Metrics
BasicAdvanced
$915M
501.30
$0.02
-
-
Price and volume
Market cap
$915M
52-week high
$19.00
52-week low
$6.11
Average daily volume
139K
Financial strength
Current ratio
3.604
Quick ratio
2.647
Long term debt to equity
0.748
Total debt to equity
1.52
Management effectiveness
Return on assets (TTM)
5.18%
Return on equity (TTM)
12.12%
Valuation
Price to earnings (TTM)
501.303
Price to revenue (TTM)
8.866
Price to book
13.37
Price to tangible book (TTM)
14.44
Price to free cash flow (TTM)
-86.033
Growth
Revenue change (TTM)
-13.01%
Earnings per share change (TTM)
-101.59%
GYRE News
AllArticlesVideos
Gyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewsWire·7 days ago
Gyre Therapeutics Announces NMPA Approval for Clinical Trial Evaluating Pirfenidone Capsules in Oncology-Related Pulmonary Complications
GlobeNewsWire·2 months ago
Gyre Therapeutics Announces Publication of Protocol for Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis in Journal of Clinical and Translational Hepatology
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Gyre Therapeutics stock?
Gyre Therapeutics (GYRE) has a market cap of $915M as of May 16, 2025.
What is the P/E ratio for Gyre Therapeutics stock?
The price to earnings (P/E) ratio for Gyre Therapeutics (GYRE) stock is 501.3 as of May 16, 2025.
Does Gyre Therapeutics stock pay dividends?
No, Gyre Therapeutics (GYRE) stock does not pay dividends to its shareholders as of May 16, 2025.
When is the next Gyre Therapeutics dividend payment date?
Gyre Therapeutics (GYRE) stock does not pay dividends to its shareholders.
What is the beta indicator for Gyre Therapeutics?
Gyre Therapeutics (GYRE) does not currently have a Beta indicator.